Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study

被引：0

作者：

Kato, T. ^{[1
]}

Kotani, D. ^{[2
]}

Takashima, A. ^{[3
]}

Satoh, T. ^{[4
]}

Masuishi, T. ^{[5
]}

Komatsu, Y. ^{[6
]}

Shiozawa, M. ^{[7
]}

Esaki, T.

Izawa, N. ^{[8
]}

Takeuchi, S. ^{[9
]}

Bando, H. ^{[10
]}

Iwasa, S. ^{[11
]}

Hasegawa, H. ^{[12
]}

Yamaguchi, T. ^{[13
]}

Taniguchi, H. ^{[5
]}

Yamada, S. ^{[14
]}

Yoshino, T. ^{[2
]}

机构：

[1] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan

[2] Natl Canc Ctr Hosp East, Kashiwa, Japan

[3] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo, Japan

[4] Kinki Univ, Dept Med Oncol, Sch Med, Osaka, Japan

[5] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[6] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[7] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[8] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Japan

[9] Kanazawa Univ Hosp, Kanazawa, Japan

[10] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Kashiwa, Japan

[11] Natl Canc Ctr, Tokyo, Japan

[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan

[13] Osaka Med & Pharmaceut Univ Hosp, Takatsuki, Japan

[14] Ono Pharmaceut, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-23

引用

页码：S21 / S22

页数：2

共 50 条

[21] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Desai, Jayesh
Kopetz, Scott
Aderka, Dan
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Ciardiello, Fortunato
Chantrill, Lorraine
Tebbutt, Niall
Strickland, Andrew
Price, Timothy
Karapetis, Chris
Murphy, Felicity
Gollerkeri, Ashwin
Golden, Adele
Edwards, Michelle L.
Tabernero, Josep
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 119 - 120
[22] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Kopetz, Scott
Aderka, Dan
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Gollerkeri, Ashwin
Golden, Adele
Edwards, Michelle L.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
Desai, Jayesh
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia Alfonso, Pilar
Price, Timothy
Strickland, Andrew
Tebbutt, Niall
Karapetis, Christos
Chantrill, Lorraine
Murphy, Felicity
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
[24] Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Tabernero, Josep
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Elez, Elena
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 273 - +
[25] Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
Smit, E.
Ahn, M-J
Dagogo-Jack, I.
Felip, E.
Gelsomino, F.
Johnson, B.
Johnson, M.
Negrao, M. V.
Offin, M.
Ramalingam, S.
Sanborn, R.
Tsao, A.
Wilner, K.
Alcasid, A.
Usari, T.
Zhang, X.
Riely, G.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S78
[26] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)
Chiu, C-F.
Yeh, Y-M.
Yeh, K-H.
Desai, J.
Price, T. J.
Tebbutt, N.
Tabernero, J.
Velez, L.
Trevino, T. L.
Grothey, A.
Yaeger, R.
Gollerkeri, A.
Maharry, K.
Kopetz, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1276 - S1276
[27] BREAKWATER: Analysis of first-line encorafenib plus cetuximab plus chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
Kopetz, Scott
Yoshino, Takayuki
Van Cutsem, Eric
Eng, Cathy
Kim, Tae Won
Wasan, Harpreet Singh
Desai, Jayesh
Ciardiello, Fortunato
Yaeger, Rona
Maughan, Timothy S.
Beyzarov, Elena
Zhang, Xiaoxi
Ferrier, Graham
Zhang, Xiaosong
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 16 - 16
[28] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
Tabernero, J.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Loupakis, F.
Hong, Y. Sang
Steeghs, N.
Guren, T. K.
Arkenau, H-T.
Garcia-Alfonso, P.
Gollerkeri, A.
Pickard, M.
Maharry, K.
Christy-Bittel, J. L.
Anderson, L.
Kopetz, S.
ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
[29] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Shuosha Li
Huabin Hu
Dong Ding
Youwen Zhu
Jin Huang
Advances in Therapy, 2021, 38 : 1650 - 1659
[30] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Li, Shuosha
Hu, Huabin
Ding, Dong
Zhu, Youwen
Huang, Jin
ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659

← 1 2 3 4 5 →